Twin Peaks Capital Ltd Purchases New Shares in Astera Labs, Inc. $ALAB

Twin Peaks Capital Ltd acquired a new position in Astera Labs, Inc. (NASDAQ:ALAB) in the 2nd quarter, Holdings Channel reports. The firm acquired 10,000 shares of the company’s stock, valued at approximately $4,830,000. Astera Labs accounts for approximately 2.4% of Twin Peaks Capital Ltd’s investment portfolio, making the stock its 10th largest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Greenleaf Trust boosted its stake in shares of Astera Labs by 1.8% during the 2nd quarter. Greenleaf Trust now owns 2,000 shares of the company’s stock valued at $966,000 after purchasing an additional 36 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in Astera Labs by 74.5% in the second quarter. Parkside Financial Bank & Trust now owns 96 shares of the company’s stock worth $46,000 after buying an additional 41 shares in the last quarter. Glenmede Trust Co. NA lifted its holdings in Astera Labs by 2.7% in the first quarter. Glenmede Trust Co. NA now owns 1,909 shares of the company’s stock worth $209,000 after buying an additional 51 shares during the period. Keating Financial Advisory Services Inc. bought a new stake in Astera Labs during the 2nd quarter valued at approximately $25,000. Finally, Integrated Wealth Concepts LLC grew its holdings in shares of Astera Labs by 0.7% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 7,006 shares of the company’s stock worth $3,384,000 after acquiring an additional 52 shares during the period. 60.47% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ALAB. Evercore reissued an “outperform” rating and issued a $297.00 target price on shares of Astera Labs in a research report on Tuesday, May 19th. Needham & Company LLC upped their price target on Astera Labs from $260.00 to $425.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Susquehanna increased their price objective on Astera Labs from $230.00 to $275.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Royal Bank Of Canada raised their price objective on Astera Labs from $425.00 to $500.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Finally, UBS Group reissued a “neutral” rating and set a $425.00 price objective on shares of Astera Labs in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $348.33.

Insider Activity at Astera Labs

In other Astera Labs news, Director Manuel Alba sold 183,000 shares of Astera Labs stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $280.13, for a total transaction of $51,263,790.00. Following the completion of the transaction, the director owned 253,863 shares in the company, valued at approximately $71,114,642.19. The trade was a 41.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Philip Mazzara sold 6,801 shares of Astera Labs stock in a transaction on Monday, August 17th. The shares were sold at an average price of $340.50, for a total value of $2,315,740.50. Following the transaction, the general counsel owned 96,542 shares of the company’s stock, valued at $32,872,551. The trade was a 6.58% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 592,244 shares of company stock worth $209,729,973 over the last quarter. 10.40% of the stock is currently owned by company insiders.

Astera Labs Stock Up 6.0%

Shares of NASDAQ ALAB traded up $15.22 on Wednesday, reaching $267.76. 1,635,366 shares of the company’s stock traded hands, compared to its average volume of 5,248,213. Astera Labs, Inc. has a 12 month low of $97.89 and a 12 month high of $499.48. The business’s 50 day simple moving average is $310.48 and its two-hundred day simple moving average is $262.88. The company has a market cap of $46.45 billion, a price-to-earnings ratio of 132.56 and a beta of 3.77.

Astera Labs (NASDAQ:ALAB) last released its earnings results on Tuesday, August 4th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.11. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The firm had revenue of $392.40 million during the quarter, compared to analyst estimates of $360.85 million. During the same period last year, the business earned $0.44 earnings per share. The business’s revenue was up 104.5% on a year-over-year basis. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. Analysts forecast that Astera Labs, Inc. will post 2.7 earnings per share for the current fiscal year.

Astera Labs Profile

Astera Labs, Inc is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help data-center operators, system manufacturers and other customers connect, expand and manage the high-speed components used in servers, storage systems and networking platforms.

The company’s portfolio includes PCI Express (PCIe) retimers and fabric switches, Compute Express Link (CXL) memory connectivity products, and Ethernet connectivity solutions.